<DOC>
	<DOCNO>NCT01962922</DOCNO>
	<brief_summary>Open label , prospective , single-center , randomize , two sequence , three period crossover study compare steady state pharmacokinetics LCP-Tacro table generic tacrolimus capsule administer twice daily stable African-American renal transplant patient .</brief_summary>
	<brief_title>Crossover Study Compare PK Once Daily LCP-Tacro Tablets Generic Tacrolimus Capsules Twice Daily .</brief_title>
	<detailed_description>This open label , prospective , single-center , randomize , two sequence , three period crossover study compare steady state pharmacokinetics daily dose LCP-Tacro tablet tacrolimus capsule administer twice daily stable African American kidney transplant patient . Approximately 72 male female African American renal transplant patient table immunosuppression regimens randomly assign 1:1 ratio one two sequence : Sequence 1 : ( n=36 ) 18 patient require less 0.15 mg/kg/day 18 patient require equal great 0.15 mg/kg/day . Patients continue generic tacrolimus capsule day 1-7 ( 24 hour PK profile day 7 ) patient switch LCP-Tacro tablet ( 15 % low dose twice daily generic tacrolimus ) day 8 . Sequence 2 : ( n=36 ) 18 patient require less 0.15 mg/kg/day 18 patient require equal great 0.15 mg/kg/day . Patients receive LCP-Tacro tablet ( 15 % low dose generic tacrolimus twice daily formulation ) day 1-7 ( 24 hour PK profile day 7 ) patient switch back twice daily generic tacrolimus treatment begin day 8 .</detailed_description>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<criteria>Inclusion criterion : Age ≥1880 old , male female African Americans Willing give write informed consent comply study visit restriction , include able speak , write understand English Pt receive primary secondary transplant Pt least 6 ( six ) mth posttransplant stable dose tacrolimus BMI ≥19 Pt seropositive Hepatitis B C positive may also enrol Pt maintain concurrent immunosuppression stable dos screen Pt proton PPI remain PPI formulation dose PK portion study . During PK phase Only : Pt take medication could interfere tacrolimus blood level , include prescription overthecounter medication , herbal food supplement ( include grapefruit , pomegranate product ) , medication must continue dose willing continue dose/routine During PK phase Only : patient schedule begin new medication could interfere tacrolimus blood level , include prescription overthecounter medication , herbal food Evidence acute rejection episode within past three month Pt AfricaAmerican Recipients organ transplant kidney Known HIV positive transplant Pt recurrent focal segmental glomerulosclerosis ( FSGS ) Pt severe medical condition ( include infection ) require acute chronic treatment Pt positive DSA Pt positive BK virus result GFR &lt; 25 ml/min measure MDRD4 SOC within last 30 day Patients AST , ALT , total bilirubin &gt; 2.5 x ULN evidence severe liver disease Pt WBC &lt; 2000/mm3 ANC &lt; 1500 mm3 PLT &lt; 75,000/mm3 HGB &lt; 8 g/dl Pt mental physical condition know nonadherence Presence intractable immunosuppressant complication side effect result dose adjustment tacrolimus Exposed investigational therapy within 30 day prior enrollment No anticipate change immunosuppressive regimen , specify study protocol Pt severe diabetic gastroparesis severe GI disturbance Pt underwent gastric band gastric bypass time pre posttransplant Pregnant nursing ( lactate ) woman , plan become pregnant Women childbearing potential , defined woman physiologically capable become pregnant unwilling use define SOC method</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>